MedTrace Logo

Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine

NCT04930003 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2023-12-07

No results posted yet for this study

Summary

Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder

Conditions

  • Covid19
  • SARS-CoV Infection
  • Vaccine Adverse Reaction

Interventions

BIOLOGICAL

QazCoVac-P -COVID-19 Subunit Vaccine

QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

OTHER

Placebo

The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)

Sponsors & Collaborators

  • Research Institute for Biological Safety Problems

    lead OTHER_GOV

Principal Investigators

  • Kunsulu Zakarya, Ph.D. · Research Institute for Biological Safety Problems

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2021-12-15
Completion
2021-12-15

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930003 on ClinicalTrials.gov